EndoBARR
Phase 2 Completed
30 enrolled 7 charts
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Phase 2 Completed
46 enrolled
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Phase 2 Completed
30 enrolled
ANGIO-TAX+
Phase 2 Completed
70 enrolled
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Phase 2 Completed
35 enrolled
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Phase 2 Completed
42 enrolled 12 charts
BOOSTER
Phase 2 Completed
155 enrolled 23 charts
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Completed
83 enrolled 10 charts
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Phase 2 Completed
169 enrolled 14 charts
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Phase 2 Completed
51 enrolled 16 charts
CUPISCO
Phase 2 Completed
529 enrolled 16 charts
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Phase 2 Completed
37 enrolled 11 charts
MK-4830-002
Phase 2 Completed
160 enrolled 19 charts
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Phase 2 Completed
454 enrolled 23 charts
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Phase 2 Completed
74 enrolled
KEYVIBE-005
Phase 2 Completed
613 enrolled
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Phase 2 Completed
41 enrolled 20 charts
Carboplatin and Bevacizumab for Recurrent Ependymoma
Phase 2 Completed
35 enrolled 17 charts
DeFianCe
Phase 2 Completed
188 enrolled
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Phase 2 Completed
105 enrolled 29 charts
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Phase 2 Completed
40 enrolled
OPAL
Phase 2 Completed
77 enrolled 8 charts
SAMCO
Phase 2 Completed
132 enrolled
BRIGHT
Phase 2 Completed
108 enrolled
GFPC 06-2018
Phase 2 Completed
150 enrolled
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
Phase 2 Completed
100 enrolled 13 charts
FMT in IT-refractory HCC - FAB-HCC Pilot Study
Phase 2 Completed
12 enrolled
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Phase 2 Completed
38 enrolled 12 charts
Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2 Completed
79 enrolled
NIVACOR
Phase 2 Completed
73 enrolled
A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Phase 2 Completed
50 enrolled
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
Phase 2 Completed
44 enrolled 15 charts
CLASSIC5
Phase 2 Completed
112 enrolled
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Phase 2 Completed
83 enrolled 17 charts
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Phase 2 Completed
25 enrolled 16 charts
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Phase 2 Completed
65 enrolled 30 charts
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Phase 2 Completed
35 enrolled 13 charts
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Phase 2 Completed
23 enrolled
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
Phase 2 Completed
20 enrolled
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Phase 2 Completed
22 enrolled 12 charts
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
13 enrolled 14 charts
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase 2 Completed
50 enrolled
Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Phase 2 Completed
43 enrolled 12 charts
ROCKET
Phase 2 Completed
62 enrolled 14 charts
SULTAN
Phase 2 Completed
20 enrolled
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2 Completed
50 enrolled
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Phase 2 Completed
53 enrolled 14 charts
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
Phase 2 Completed
60 enrolled 23 charts
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Phase 2 Completed
133 enrolled 13 charts
TASCO1
Phase 2 Completed
154 enrolled 15 charts